drugset / Trial / NCT05177926
Preventing Mother-to-child Transmission of Hepatitis B Virus With Tenofovir Alafenamide (TAF)
Phase 4
Unknown
330 enrolled
Nanfang Hospital, Southern Medical University
Gilead Sciences · collabTigermed Consulting Co., Ltd · collab
NaSingle-groupOpen-labelPrevention
Summary
The purpose of this study is to evaluate the efficacy and safety of Tenofovir alafenamide (TAF) for prevention of mother-to-child transmission of hepatitis B virus among pregnant women with high level HBV DNA.
Timeline
- Start
- 2021-04-04
- Primary completion
- 2023-12-31
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | tenofovir alafenamide | Small molecule | 25 mg | Oral |